Administration of a gonadotropin-releasing hormone agonist during pregnancy: follow-up of 28 pregnancies exposed to triptoreline
E Elefant, B Biour, J Blumberg-Tick, C Roux, F Thomas, E Elefant, B Biour, J Blumberg-Tick, C Roux, F Thomas
Abstract
Objective: To evaluate the teratogenic or fetal risk of a long-acting GnRH agonist (GnRH-a) triptoreline acetate (Decapeptyl; Ipsen-Biotech, Inc., Paris, France), inadvertently administrated in the first weeks of pregnancy.
Design: Prospective follow-up of exposed pregnancies and case reports.
Setting: Teratology information service of a public hospital and pharmacovigilance department of the firm.
Patients: Inadvertent pregnant women receiving a treatment, mainly for endometriosis or IVF.
Interventions: Case by case, individual estimations of the risks have been provided.
Main outcome measure: Each pregnancy issue has been analyzed.
Results: No teratogenic or fetal toxic effect has been noted.
Conclusion: No specific hazard has been observed among newborns after inadvertent exposures to a GnRH-a during the first 20 weeks of pregnancy.
Source: PubMed